ResearchMoz.us include new market research report"Hyperlipidemia Prescription Drugs Market (http://www.researchmoz.us/hyperlipidemia-prescription-drugs-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019-report.html) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 " to its huge collection of research reports.
Hyperlipidemia refers to abnormal elevation of lipids and/or lipoprotein levels. Risk factors associated with such condition include stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension and other cardiovascular diseases. Drugs which are used to treat hyperlipidemia act by either accelerating the elimination of lipoproteins from the body or decrease production of lipoproteins. These medications not only lower the unwanted cholesterol levels but also prove to be vital for lowering the risk of heart attacks or strokes.
The global hyperlipidemic prescription drugs market is categorized based on drug classes namely:
HMG COA reductase inhibitors
Fibric acid derivatives
Bile acid sequestrating agents
Cholesterol absorption inhibitors
Combination drug therapy
North America currently dominates the global hyperlipidemia prescription drugs market and is followed by Europe due to high prevalence of diseases associated with elevated levels of lipoproteins and the growing baby boomer population. Emerging economies of Asia-Pacific, Latin America and Middle East are also expected to undergo rapid market growth for hyperlipidemic drugs.
One of the major factors driving the global hyperlipidemic prescription drugs market is increasing susceptibility to heart diseases associated with aging population. Other factors such as patent expiration and the consequent genericization in the market, availability of funding and undertaking of health awareness programs by healthcare centers, high incidence rates of cardiovascular diseases and rising awareness among people for reducing the harmful cholesterol levels to control heart diseases. A large number of hyperlipidemia drugs are in phase III of clinical trials for their assessment in providing clinical benefits and long-term safety records.
Reasons for Buying this Report
This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a technological growth map over time to understand the industry growth rate
It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
It provides distinctive graphics and exemplified SWOT analysis of major market segments